Five-year results of ICG-Guided Photodynamic Therapy combined with intravitreal Ranibizumab for juxtapapillary polypoidal choroidal vasculopathy with macular involvement

被引：0
|
作者：
Petropoulos, I. K. [1 ]
Matter, M. A. [1 ]
Desmangles, P. M. [1 ]
机构：
[1] Ophthalmol Ctr Rive, Geneva, Switzerland
来源：
ACTA OPHTHALMOLOGICA | 2014年 / 92卷
关键词：
D O I：
10.1111/j.1755-3768.2014.F070.x
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
F070
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab
    Masayuki Hata
    Akitaka Tsujikawa
    Masahiro Miyake
    Kenji Yamashiro
    Sotaro Ooto
    Akio Oishi
    Isao Nakata
    Ayako Takahashi
    Nagahisa Yoshimura
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253 : 189 - 197
  • [22] Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy
    Yoshida, Yusaku
    Kohno, Takeya
    Yamamoto, Manabu
    Yoneda, Tasuku
    Iwami, Hisashi
    Shiraki, Kunihiko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2013, 57 (03) : 283 - 293
  • [23] Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab
    Tan, C. S.
    Ngo, W. K.
    Lim, L. W.
    Lim, T. H.
    EYE, 2015, 29 (09) : 1238 - 1238
  • [24] Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy
    Yusaku Yoshida
    Takeya Kohno
    Manabu Yamamoto
    Tasuku Yoneda
    Hisashi Iwami
    Kunihiko Shiraki
    Japanese Journal of Ophthalmology, 2013, 57 : 283 - 293
  • [25] 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
    Ian Y. Wong
    Xuan Shi
    Rita Gangwani
    Paul Zhao
    Lawrence P. Iu
    Qing Li
    Alex Ng
    Xiaoxin Li
    BMC Ophthalmology, 15
  • [26] Choroidal Thickness Changes After Intravitreal Ranibizumab and Photodynamic Therapy in Recurrent Polypoidal Choroidal Vasculopathy
    Maruko, Ichiro
    Iida, Tomohiro
    Oyamada, Hiroshi
    Sugano, Yukinori
    Ojima, Akira
    Sekiryu, Tetsuju
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 156 (03) : 548 - 556
  • [27] Factors influencing the outcome of polypoidal choroidal vasculopathy following combined treatment with photodynamic therapy and intravitreal ranibizumab
    C S Tan
    W K Ngo
    L W Lim
    T H Lim
    Eye, 2015, 29 : 1238 - 1238
  • [28] 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
    Wong, Ian Y.
    Shi, Xuan
    Gangwani, Rita
    Zhao, Paul
    Iu, Lawrence P.
    Li, Qing
    Ng, Alex
    Li, Xiaoxin
    BMC OPHTHALMOLOGY, 2015, 15
  • [29] Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy
    Sakai, Tsutomu
    Okano, Kiichiro
    Kohno, Hideo
    Tsuneoka, Hiroshi
    ACTA OPHTHALMOLOGICA, 2016, 94 (08) : E765 - E771
  • [30] Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy
    Ito, Arisa
    Maruyama-Inoue, Maiko
    Kitajima, Yoko
    Sato, Shimpei
    Inoue, Tatsuya
    Yamane, Shin
    Kadonosono, Kazuaki
    PLOS ONE, 2020, 15 (06):
12345